{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T06:16:00Z","timestamp":1776665760697,"version":"3.51.2"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To ascertain renal cell carcinoma (RCC) financial toxicity on COVID-19 during the COVID-19 crisis as patients are struggling with therapeutic and financial implications.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>An online survey was conducted from March 22 to March 25, 2020. It included baseline demographic, clinicopathologic, treatment-related information, anxiety levels related to COVID-19, questions related to financial concerns about COVID-19 as well as the validated 11-item COST measure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Five-hundred-and-thirty-nine patients (39%:58% male:female) from 14 countries responded. 23% of the patients did not feel in control of their financial situation but 8% reported being very satisfied with their finances. The median COST score was 21.5 (range 1\u201344). Metastatic patients who have not started systemic therapy had a COST score (19.8 range 2\u201341) versus patients on oral systemic therapy had a COST score (23.9 range 4\u201344). Patients in follow-up after surgery had a median COST score at 20.8 (range 1\u201340). A low COST scores correlated (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) were female gender (<jats:italic>r<\/jats:italic>\u2009=\u20090.108), younger age (<jats:italic>r<\/jats:italic>\u2009=\u20090.210), urban living situation (<jats:italic>r<\/jats:italic>\u2009=\u20090.68), a lower educational level (<jats:italic>r<\/jats:italic>\u2009=\u20090.155), lower income (<jats:italic>r<\/jats:italic>\u2009=\u20090.165), higher anxiety about acquiring COVID-19 (<jats:italic>r<\/jats:italic>\u2009=\u20090.198), having metastatic disease (<jats:italic>r<\/jats:italic>\u2009=\u20090.073) and a higher distress score about cancer progression (<jats:italic>r<\/jats:italic>\u2009=\u20090.224).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our data highlight severe financial impact of COVID-19. Acknowledging financial hardship and thorough counseling of cancer patients should be part of the conversation during the pandemic. Treatment and surveillance of RCC patients might have to be adjusted to contemplate financial and medical needs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00345-020-03476-6","type":"journal-article","created":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T08:02:41Z","timestamp":1603353761000},"page":"2559-2565","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["COVID-19 and financial toxicity in patients with renal cell carcinoma"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4574-6522","authenticated-orcid":false,"given":"Michael D.","family":"Staehler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dena J.","family":"Battle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiane D.","family":"Bergerot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumanta Kumar","family":"Pal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David F.","family":"Penson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,22]]},"reference":[{"key":"3476_CR1","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMe2002387","volume":"382","author":"AS Fauci","year":"2020","unstructured":"Fauci AS, Lane HC, Redfield RR (2020) Covid-19 - navigating the uncharted. N Engl J Med 382:1268\u20131269","journal-title":"N Engl J Med"},{"key":"3476_CR2","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/trf.15789","volume":"60","author":"MB Pagano","year":"2020","unstructured":"Pagano MB, Hess JR, Tsang HC et al (2020) Prepare to adapt: Blood supply and transfusion support during the first 2 weeks of the 2019 Novel Coronavirus (COVID-19) pandemic affecting Washington State. Transfusion 60:908\u2013911","journal-title":"Transfusion."},{"key":"3476_CR3","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.7560","author":"M Ueda","year":"2020","unstructured":"Ueda M, Martins R, Hendrie PC et al (2020) Managing cancer care during the COVID-19 pandemic: agility and collaboration toward a common goal. J Natl Compr Canc Netw. https:\/\/doi.org\/10.6004\/jnccn.2020.7560","journal-title":"J Natl Compr Canc Netw"},{"key":"3476_CR4","doi-asserted-by":"crossref","first-page":"153473542091281","DOI":"10.1177\/1534735420912811","volume":"19","author":"G Yang","year":"2020","unstructured":"Yang G, Zhang H, Yang Y (2020) Challenges and countermeasures of integrative cancer therapy in the epidemic of COVID-19. Integr Cancer Ther 19:1534735420912811","journal-title":"Integr Cancer Ther"},{"key":"3476_CR5","doi-asserted-by":"publisher","first-page":"4181","DOI":"10.1002\/cncr.31643","volume":"124","author":"M Pisu","year":"2018","unstructured":"Pisu M, Henrikson NB, Banegas MP, Yabroff KR (2018) Costs of cancer along the care continuum: what we can expect based on recent literature. Cancer 124:4181\u20134191","journal-title":"Cancer"},{"key":"3476_CR6","unstructured":"UNACD. The coronavirus shock: another story of a global crisis foretold and what policymaker should be doin about it. https:\/\/unctad.org\/2020. Accessed 19 Apr 2020"},{"key":"3476_CR7","doi-asserted-by":"publisher","first-page":"100269","DOI":"10.1016\/j.eclinm.2020.100269","volume":"20","author":"A Desai","year":"2020","unstructured":"Desai A, Gyawali B (2020) Financial toxicity of cancer treatment: moving the discussion from acknowledgement of the problem to identifying solutions. EClinicalMedicine 20:100269","journal-title":"EClinicalMedicine"},{"key":"3476_CR8","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1002\/cncr.28814","volume":"120","author":"JA de Souza","year":"2014","unstructured":"de Souza JA, Yap BJ, Hlubocky FJ et al (2014) The development of a financial toxicity patient-reported outcome in cancer: the COST measure. Cancer 120:3245\u20133253","journal-title":"Cancer"},{"key":"3476_CR9","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1002\/cncr.31913","volume":"125","author":"Z Zheng","year":"2019","unstructured":"Zheng Z, Jemal A, Han X et al (2019) Medical financial hardship among cancer survivors in the United States. Cancer 125:1737\u20131747","journal-title":"Cancer"},{"key":"3476_CR10","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/cncr.30369","volume":"123","author":"JA de Souza","year":"2017","unstructured":"de Souza JA, Yap BJ, Wroblewski K et al (2017) Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive Score for financial Toxicity (COST). Cancer 123:476\u2013484","journal-title":"Cancer"},{"key":"3476_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fonc.2019.00011","volume":"9","author":"CD Bergerot","year":"2019","unstructured":"Bergerot CD, Battle D, Bergerot PG et al (2019) Sources of frustration among patients diagnosed with renal cell carcinoma. Front Oncol 9:11","journal-title":"Front Oncol"},{"key":"3476_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/hex.12628","volume":"21","author":"BJ Addario","year":"2018","unstructured":"Addario BJ, Fadich A, Fox J et al (2018) Patient value: perspectives from the advocacy community. Health Expect 21:57\u201363","journal-title":"Health Expect"},{"key":"3476_CR13","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","volume":"382","author":"B Cao","year":"2020","unstructured":"Cao B, Wang Y, Wen D et al (2020) A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med 382:1787\u20131799","journal-title":"N Engl J Med."},{"key":"3476_CR14","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1056\/NEJMp2004211","volume":"382","author":"WE Parmet","year":"2020","unstructured":"Parmet WE, Sinha MS (2020) Covid-19 - the law and limits of quarantine. N Engl J Med 382:e28","journal-title":"N Engl J Med"},{"key":"3476_CR15","doi-asserted-by":"publisher","first-page":"104786","DOI":"10.1016\/j.antiviral.2020.104786","volume":"178","author":"KT Choy","year":"2020","unstructured":"Choy KT, Wong AY, Kaewpreedee P et al (2020) Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res 178:104786","journal-title":"Antiviral Res"},{"key":"3476_CR16","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.2174\/0929867327666200416131117","volume":"27","author":"M Costanzo","year":"2020","unstructured":"Costanzo M, De Giglio MAR, Roviello GN (2020) SARS CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir\/Ritonavir, Darunavir\/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus. Curr Med Chem 27:4536\u20134541","journal-title":"Curr Med Chem."}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-020-03476-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-020-03476-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-020-03476-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T23:36:27Z","timestamp":1634859387000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-020-03476-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,22]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["3476"],"URL":"https:\/\/doi.org\/10.1007\/s00345-020-03476-6","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,22]]},"assertion":[{"value":"27 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Ethics board approval was not obtained as these data were not obtained via an institution, but by a patient organization (KCCure).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients gave informed consent and voluntarily entered their data by themselves in the database.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}